Literature DB >> 7284698

Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.

A Kalir, A Sabbagh, M B Youdim.   

Abstract

1 A number of aromatic-N-propargyl (acetylenic) compounds and indoleamines were tested for their inhibitory action on monoamine oxidase (MAO) type A and type B using the substrates 5-hydroxytryptamine (5-HT), beta-phenylethylamine (PEA) and dopamine. 2 Structure activity studies with aromatic-N-propragyl (acetylenic) derivatives have shown that MAO inhibitory potency is least dependent on the aromatic portion of the compounds. N-methylated propargyl derivatives are the most active and replacement of the methyl group with a higher alkyl or aromatic group results in significant reduction of activity. The triple bond in the N-propargyl portion is absolutely essential for activity and must be beta-to the nitrogen. It is the acetylenic group that gives these compounds their irreversible MAO inhibitory property. 3 The present study has indicated that since the acetylenic compounds resemble the enzyme substrates the distance between the aromatic ring and the N-propargyl terminal is crucial in designating the type A or type B MAO inhibitory property. For MAO type A inhibition, a distance equivalent to at least three carbon units is required, while for the inhibition of the B type enzyme this distance can be 1 or 2 carbon units. 4 The compounds AGN-1133 and AGN-1135 show most promise in Parkinson's disease or as anti-depressants because of their irreversible selective type B MAO inhibition in vitro and in vivo. 5 A number of indoleamine derivatives were found to be reversible selective type A inhibitors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284698      PMCID: PMC2071835          DOI: 10.1111/j.1476-5381.1981.tb16771.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Factors affecting morphine uptake into kidney slices.

Authors:  D N Teller; T De Guzman; A Lajtha
Journal:  Biochem Pharmacol       Date:  1976-06-01       Impact factor: 5.858

2.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

3.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

4.  A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes.

Authors:  M D Houslay; K F Tipton
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

5.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

6.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

7.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

8.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

9.  Synthesis and pharmacological activity of alkylated tryptamines.

Authors:  A Kalir; S Szara
Journal:  J Med Chem       Date:  1966-05       Impact factor: 7.446

10.  Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.

Authors:  A R Green; M B Youdim
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

View more
  22 in total

Review 1.  Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Authors:  L I Golbe; J W Langston; I Shoulson
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

Review 4.  The discovery and development of rasagiline as a new anti-Parkinson medication.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2020-01-23       Impact factor: 3.575

5.  Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

Authors:  Zaid A Abassi; Ofer Binah; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

6.  Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

Authors:  J Semba; G Curzon; P N Patsalos
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

Review 7.  DSP4, a selective neurotoxin for the locus coeruleus noradrenergic system. A review of its mode of action.

Authors:  Svante B Ross; Carina Stenfors
Journal:  Neurotox Res       Date:  2014-06-26       Impact factor: 3.911

8.  Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells.

Authors:  G Yadid; O Zinder; M B Youdim
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

Review 9.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.